---
title: The Efficacy of Pyridostigmine Therapy After Transurethral Resection of Prostate in Cases with Underactive Urinary Bladder.
nct_id: NCT06753071
overall_status: COMPLETED
phase: PHASE4
sponsor: Menoufia University
study_type: INTERVENTIONAL
primary_condition: Underactive Bladder
countries: Egypt
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06753071.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06753071"
ct_last_update_post_date: 2025-03-26
last_seen_at: "2026-05-12T07:21:41.085Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# The Efficacy of Pyridostigmine Therapy After Transurethral Resection of Prostate in Cases with Underactive Urinary Bladder.

**Official Title:** The Efficacy of Pyridostigmine Therapy After Transurethral Resection of Prostate in Cases with Underactive Urinary Bladder: Prospective Randomized Trial

**NCT ID:** [NCT06753071](https://clinicaltrials.gov/study/NCT06753071)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE4
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 66
- **Lead Sponsor:** Menoufia University
- **Conditions:** Underactive Bladder, TURP(transurethral Resection of Prostate), BPH (Benign Prostatic Hyperplasia)
- **Start Date:** 2024-04-01
- **Completion Date:** 2025-01-01
- **CT.gov Last Update:** 2025-03-26

## Brief Summary

The efficacy of pyridostigmine therapy after transurethral resection of prostate in cases with underactive urinary bladder

## Detailed Description

Underactive bladder is a decrease in detrusor contraction and/or shortening of the contraction time, resulting in an incomplete and/or prolongation of the bladder emptying within the normal time frame. Prolonged bladder outlet obstruction due to prostatic enlargment one of the main causes of bladder hypocontractility. To make a diagnosis, it is necessary to perform a pressure-flow study. Decrease in maximum urine flow rate related to bladder outlet obstruction or poor contractility can be distinguished by pressure-flow study.

parasympathomimetics (cholinergic receptor stimulating agents) could be beneficial for patients with underactive bladder. However, no systematic review with meta-analysis addressing potential benefits or adverse effects exists. Pyridostigmine is a medication used to treat myasthenia gravis and underactive bladder as well.

Patients with underactive bladder after transurethral resection of prostate may still complain of recurrent attacks of obstructive lower urinary tract symptoms.

## Eligibility

- **Minimum age:** 45 Years
- **Maximum age:** 75 Years
- **Sex:** MALE
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Patients who are not younger than 45 or older than 75 years.
* Patients with benign prostatic hyperplasia who are eligible for transurethral resection of prostate.
* Patients who has decreased bladder contractility confirmed by urodynamic study (pressure flow study) and plotted on international continence society (ICS) nomogram.

Exclusion Criteria:

* Patients younger than 45 or older than 75 years.
* Patients who have diabetes.
* Patients with a history of neurological diseases.
* patients with a previous history of pelvic surgery.
```

## Arms

- **Pyridostigmine group** (ACTIVE_COMPARATOR) — this group will receive pyridostigmine 60 mg twice daily.
- **Control group** (PLACEBO_COMPARATOR) — This will receive placebo postoperatively.

## Interventions

- **Pyridostigmine oral tablet** (DRUG) — Pyridostigmine oral tablet, 60 mg, twice daily, for 3 months
- **Placebo** (DRUG) — Placebo oral tablet, twice daily, for 3 months

## Primary Outcomes

- **Severity of lower urinary tract symptoms** _(time frame: 1, 2 , 3 months postoperative)_ — Severity of lower urinary tract symptoms will be assessed by International Prostate Symptom Score (IPSS) and expressed in number. A score of 0 to 7 indicates mild symptoms, 8 to 19 indicates moderate symptoms and 20 to 35 indicates severe symptoms.
- **Maximum urine flow rate** _(time frame: 1, 2 , 3 months postoperative)_ — Maximum urine flow rate will be assessed by flowmetry and measured by milliliter per second.
- **Post-void residual volume** _(time frame: 1, 2 , 3 months postoperative)_ — Post-void residual volume will be assessed by ultrasound assessment and measured by centimeter cubic.
- **Bladder contractility evaluation** _(time frame: 1, 2 , 3 months postoperative)_ — Bladder contractility will be assessed by urodynamic study. Contractility index is expressed in numbers as follows: strong \> 150, normal 100-150, and weak \< 100.
- **Bladder detrusor pressure assessment** _(time frame: 1, 2 , 3 months postoperative)_ — Bladder detrusor pressure will be assessed by urodynamic study and detrusor pressure measured by CmH2O.

## Locations (1)

- Menoufia Faculty of Medicine, Shebin El-Kom, Menoufia, Egypt

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.menoufia faculty of medicine|shebin el-kom|menoufia|egypt` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06753071.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06753071*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*